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Abstract 
Platelets play roles in malignancy, wound healing, and immunity. Nevertheless, their 
significance in postoperative outcomes is not established. This is a retrospective cohort 
study of 100,795 patients undergoing cancer surgery in 2010 and 2014 in >500 
hospitals. Patients were stratified into five groups based on preoperative platelet counts. 
Multivariable logistic regression was used to determine the risk of 30-day mortality, 
morbidities, readmission, and prolonged hospitalization using the mid-normal group as a 
reference. We adjusted for demographic variables, comorbidities, and operation 
complexity. In the 2014 cohort, multivariable analysis showed that mortality was higher 
in patients with thrombocytopenia (OR 1.49, 95% CI [1.23-1.81]), high-normal platelets 
(OR 1.29, [1.06-1.55]), and thrombocytosis (OR 1.78, [1.45-2.19]). Composite 
postoperative morbidity followed a similar trend with thrombocytopenia (OR 1.34, [1.25-
1.43]), high-normal counts (OR 1.41, [1.33-1.49]), and thrombocytosis (OR 2.20, [2.05-
2.36]). Concordantly, the risks of prolonged hospitalization and 30-day readmission 
followed the same pattern. These results were validated in a large colon cancer cohort 
from the 2010 database. In conclusion, platelet count is a prognostic indicator in cancer 
surgeries. This could be related to the role of platelets in wound healing and immunity 
on one hand, and propagating malignancy on the other. 
Keywords: Thrombocytes, oncology, mortality, morbidity 
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Introduction 
Cancer patients are prone to alteration in their platelet counts due to the direct effect of 
cancer, chronic inflammatory state, or as a result of cancer therapy. Pretreatment 
platelet counts have been studied in a variety of cancers and high counts uniformly 
correlated with worse outcomes.[1, 2] Such studies have been limited by relatively small 
sample sizes, lack of generalizability, and confinement to specific cancer types and 
hospitals. On the other hand, platelets contribute to vital processes such as hemostasis, 
clearing infections, and wound healing.[3, 4] From a surgical standpoint, the significance 
of platelet counts in predicting potentially preventable post-operative morbidity and 
mortality has not been investigated. Of note, another blood count parameter, 
preoperative hemoglobin level, predicts postoperative morbidity and mortality.[5] This 
highlights the utility of such entities in identifying high risk surgical patients who are in 
this case undergoing cancer-related surgeries.     
Preclinical studies provide ample evidence for the contribution of platelets to 
malignancy. We have shown that platelets promote cancer by suppressing adaptive 
anti-tumor immunity.[6] Moreover, platelets with deficient activation mechanisms are 
less likely to mediate metastasis.[7] Tumor cells in turn are capable of activating 
platelets, a process termed tumor cell-induced platelet aggregation (TCIPA), which 
engages platelets in protecting malignant cells from the immune system.[8] Thrombin 
derived from cancer cells stimulates their adhesion to platelets and promotes 
metastasis.[9] In fact, tumor ability for TCIPA correlates with its metastatic potential.[10] 
Platelets also release angiogenic factors such as VEGF and angiopoietin,[11, 12, 13] 
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promoting cancer nourishment, and can promote mitogenesis via a TGFβ-dependent 
mechanism.[14]  
Cancer patients are also in a thrombophilic state as evidenced by thrombocytosis and 
elevated markers of platelet activation such as P-selectin in circulation, the latter of 
which correlates with venous thromboembolism.[15] Platelet microparticles (PMPs), 
released upon platelet activation, are elevated in cancer patients compared to controls 
and their level correlates with metastasis.[16] One mechanism promoting 
thrombopoiesis in malignancy involves IL-6-induced thrombopoietin production by the 
liver.[17]  
Contrasting with their detrimental contributions to cancer, platelets have vital functions 
besides hemostasis. They participate in host defense against pathogens such as 
bacterial clearance from circulation through promoting their uptake by dendritic cells,[18] 
engulfment from Kuppfer cells,[19] or via release of cytokines with antimicrobial 
activities.[20] Given the state of immunosuppression which often complicates 
malignancy, such role for platelets in protection from pathogens could be particularly 
essential. Moreover, given that platelets are among the first cellular entities to arrive at 
the site of tissue injury, they have a major role in tissue healing and regeneration, via 
molecules such as platelet-derived growth factor (PDGF)[21] and stromal cell-derived 
factor-1.[4] Platelet-rich plasma is indeed used in osteoarthritis, a wear and tear process 
that can be reversed by the regenerative properties of platelets.[22]  
In addition, platelets are qualitatively altered in the setting of cancer. Platelets from 
glioma and prostate cancer patients carry tumor-derived mutant RNA, and those from 
glioma patients have a distinct RNA signature compared to normal controls.[23] Given 
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the interaction between platelets and the immune system, it is conceivable that platelet 
count is often reflective of the systemic inflammatory state. Thus, cancer patients often 
show thrombocytosis secondary to this inflammatory milieu, or thrombocytopenia due to 
cancer-induced bone marrow suppression, platelet consumption by cancer-induced 
aggregation, or as a result of chemotherapy. Therefore, pre-operative platelet count 
could prove to be a useful, biologically sound indicator of the toll of cancer on these 
patients and their risk for future morbidities such as infections and thromboembolism. 
In this study, we investigate the significance of preoperative platelet counts in predicting 
30-day morbidity, mortality, and readmission, and total hospital length of stay in patients 
undergoing cancer surgeries across different cancer types. We analyze data from the 
American College of Surgeons’ National Surgical Quality Improvement Program (ACS 
NSQIP) database. The NSQIP database is a well validated and robust patient registry. It 
resulted in tangible improvements in the performance of participating hospitals, 
including steady reductions in mortality and morbidity, as well as cutting healthcare 
expenses.[24, 25, 26, 27] 
Methods 
Study design 
This is a retrospective cohort study analyzing data from the National Surgical Quality 
Improvement Program (NSQIP), which includes hundreds of voluntarily participating 
non-Veterans Affairs hospitals in the United States and international sites. These 
hospitals prospectively provide the NSQIP registry with data on patients undergoing 
major surgeries in the inpatient and outpatient settings. Data includes preoperative 
6 
 
medical conditions and lab values, intraoperative events, and postoperative morbidity 
and mortality until 30 days after surgery,[28] extending well beyond their discharge from 
the hospital. The purpose of this program is to provide continuous feedback to the 
participating hospitals to identify areas where improvement needs to be made. Data is 
collected by trained site Surgical Clinical Reviewers (SCRs) and transmitted to the 
national NSQIP registry. This information is collected directly from the patient’s chart 
and if necessary, from phone calls and letters to patients. This data collection process is 
continuously subject to Inter-Rater Reliability Audit which ensures accurate data 
deposition.[29] Participating hospital training and audit procedures have ensured robust 
and effective data deposition in the NSQIP database.[28, 29, 30] This program has 
resulted in marked improvements in postoperative outcomes in the participating 
hospitals.[24, 25, 27]  
In this study, we used the 2014 Participant Use Data File (PUF), which includes 
750,397 cases from 517 hospitals. Cancer cases were then extracted using 
postoperative diagnosis ICD-9 codes (140-209.39 and 209.7-209.79), amounting to a 
total of 100,877 cases. Platelet count was available for 90,735 cases, which were used 
for analysis. For patients undergoing more than one surgery, the index case was used. 
To validate our findings, an independent cohort of 10,060 colon cancer patients was 
analyzed using the 2010 PUF.  
Patients in the 2014 and 2010 datasets were divided into five categories based on their 
latest preoperative platelet count before the index surgery (x103/µL): <150 (I), 150-232 
(II), 233-316 (III), 317-400 (IV) and >400 (V). These categories reflect thrombocytopenia 
(I), thrombocytosis (V), and the normal range divided into three equal intervals (II-IV). 
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Descriptive statistics were used to summarize baseline demographic variables, 
preoperative morbidities, and preoperative lab values (Table I).  
The primary endpoints of this study were mortality and composite morbidity within 30 
days from the date of surgery. Secondary endpoints included hospitalization for five or 
more days, readmission for any cause within 30 days from operation (available for the 
2014 dataset only), and organ-specific morbidities within 30 days from surgery. Specific 
morbidities included: cardiac (myocardial infarction or cardiac arrest), respiratory 
(pneumonia, ventilator support >48h, or unplanned intubation), neurological 
(cerebrovascular accident), urinary (progressive renal insufficiency, acute renal failure, 
or urinary tract infection), wound complication (superficial, deep incisional/organ space 
surgical site infection, or wound dehiscence), hematological (blood transfusion within 
72h postoperatively), sepsis, and venous thromboembolic (deep venous thrombosis or 
pulmonary embolism) events. Composite morbidity included the occurrence of any of 
the above specific morbidities. A comprehensive description of all variables is available 
in the ACS NSQIP Participant Use Data File (PUF) user guide (www.facs.org, 2017). 
There was no role for any funding source in the study design, collection, analysis and 
interpretation of data, writing of the report, or the decision to submit the article for 
publication. 
Inclusion and exclusion criteria 
This database includes major surgical cases in the inpatient and outpatient settings, as 
determined by their Current Procedural Terminology (CPT®) code, which is updated 
annually as new codes become available. Exclusion criteria consist of the following: 
patients under the age of 18 years, brain dead organ donors, cases involving 
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Hyperthermic Intraperitoneal Chemotherapy (HIPEC), trauma cases, and transplant 
cases (transplant procedure and any additional surgical procedure during the transplant 
hospitalization is excluded). To ensure diversity of collected cases, for programs other 
than small and rural hospitals, the database excludes cases beyond three per 8-day 
sampling cycle for the following procedures: inguinal herniorrhaphy, breast lumpectomy, 
laparoscopic cholecystectomy, transurethral resection of the prostate (TURP), and 
transurethral resection of bladder tumor (TURBT). Cases beyond the required number 
in a given site are also excluded. Returns to the operating room related to a 
complication of a prior procedure are also excluded, and so are multiple NSQIP 
assessed cases within 30 days: any patient who already has a NSQIP-assessed 
procedure entered within the previous 30 days. 
Hospital exclusion criteria: To maintain a high level of data quality, only cases included 
in the hospital performance analysis are included in the PUF database analyzed in this 
study. Such cases go through another level of scrutiny which ensures their accuracy. A 
site is excluded if the 30-day follow-up rate is <80% or their Inter-Rater Reliability Audit 
disagreement is >5%.  
Statistical analysis 
For baseline variables (Table I), categorical variables were summarized with 
percentages and continuous variables were summarized with means and 95% 
confidence intervals. χ2 and Analysis of Variance (ANOVA) tests were used for 
categorical and continuous variables, respectively. For outcome analysis, a univariate 
logistic regression was used to present the unadjusted odds ratios (ORunadjusted) and 
associated 95% confidence intervals (CI) in which each outcome variable was 
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regressed on the group variable (platelet counts group) only.  Second, to assess the risk 
factors for each outcome variable (30-day mortality, composite morbidity, hospital stay 
>5 days, and 30-day readmission), a logistic regression analysis was performed. In 
these models, each of the outcome variables was regressed on group variable and on 
each of the baseline variables, one at a time. Then a separate multiple logistic 
regression model was used for each outcome variable with adjusted odds ratios. Two 
levels of adjustment were used: OR1 (with 95% CI) is the adjusted odds ratio with basic 
adjustment for age, gender, race, work relative value unit, American Society of 
Anesthesiologists class, and functional status. OR2 (with 95% CI) is the adjusted odds 
ratio with further adjustment of comorbidities and clinically relevant variables besides 
adjusting for covariates in OR1 (Supplementary table I). Data for this study was nearly 
complete for all variables, except for a fraction of preoperative lab values 
(Supplementary table II). Lastly, we fit a separate stratified multiple logistic regression 
model for each outcome with adjustment: OR2 is the odds ratio (with 95% CI) in which 
we regress each outcome on the above-mentioned basic covariates (in OR1) and 
additional clinically relevant covariates (Supplementary table I). All statistical analyses 
were performed using SAS 9.4 software (SAS Institute, Cary, North Carolina). 
Results 
Baseline variables 
The 2014 cohort included 90,735 patients with known platelet counts. The mean age 
was 62.53 (±13.42) years and 56.07% were females. The majority of patients (90.9%) 
had platelet counts within a month before surgery. Patients were divided into five 
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categories based on platelet counts: thrombocytopenia (I), low-normal (II), mid-normal 
(III), high-normal (IV), and thrombocytosis (V) (Table I). Groups I, IV, and V constituted 
24.87% of the patients and were more likely to have comorbidities.  
Lower platelet counts were associated with older age, male gender, a co-existing 
bleeding disorder, diabetes mellitus requiring medication, and chronic steroid use. 
Higher platelet counts (groups IV and V) were associated with tobacco use, infected 
surgical wounds, and sepsis in the 48 hours preceding surgery.  
Patients with thrombocytopenia or thrombocytosis were less likely to be in ASA classes 
I and II, had slightly more complex cases (as indicated by RVU), and had longer 
operation times. They were also more likely to have weight loss >10%, BMI <18.5, 
disseminated cancer, and albumin <35 g/L.  
Groups I, IV, and V were more likely to spend one or more days in the hospital prior to 
surgery, receive a preoperative transfusion, and to have abnormal preoperative lab 
values.  
Table I also includes the frequencies of the seven most common cancers in the US. 
Cancer types were differentially distributed among platelet groups; for example, prostate 
cancer was more likely to associate with lower platelet counts than colon cancer. 
Preoperative platelet counts predict postoperative morbidity, mortality, hospital 
length of stay, and readmission rate in the 2014 cohort 
Group III was used as a reference to estimate the significance of platelets across the 
whole range of platelet counts. Crude mortality, composite morbidity, readmission within 
30 days, and hospitalization for at least five days (above the average) were all higher in 
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groups I, IV, and V (Table II). This pattern persisted after adjusting for comorbidities and 
possible confounders in models 1 and 2 (Supplementary table I). When specific 
morbidities were investigated, a similar trend was observed. This included cardiac, 
respiratory, neurological, urinary, wound, infectious, venous thromboembolic, and 
hematological morbidities, all uniformly showing increased risk in categories I, IV, and V 
(Table II).  
Platelet prognostic significance stratified by age, gender, and cancer 
dissemination 
Patients were stratified by age (<65 or ≥65 years), gender, and cancer status 
(disseminated or regional/local). To further dissect the role of platelets in 
dictating/predicting postoperative outcomes, we adjusted for additional variables such 
as postoperative diagnosis (PODIAG) and preoperative hematocrit (PRHCT). 
Extensively adjusting for variables is often unnecessary and can lead to over-
adjustment bias.[31] Regarding postoperative diagnosis, this is particularly true since 
the significance of platelets should be tested in individual cancer types, regardless of 
adjusting in the current analysis. As for hematocrit, its level can be associated with 
platelet count either in a causal or bystander manner. However, in the stratified analysis 
(Table III), PODIAG and PRHCT were included in the adjustment models for more 
conservative observations. Stratifying patients by age, gender, and cancer 
dissemination, the association of platelets with outcomes persisted. Univariate and 
multivariate analyses showed that 30-day mortality was higher in groups I and V, and 
composite morbidity was increased in groups I, IV, and V (Table III).    
Platelets in colon cancer: a validation dataset 
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The above analyses were based on the 2014 NSQIP cohort. To validate the utility of 
platelet counts in predicting outcomes, an independent NSQIP cohort from a different 
year (2010) was analyzed, where all the patients had surgeries with a postoperative 
diagnosis of colon cancer (Table IV). Colon cancer was chosen because it included the 
highest number of cases with a relatively balanced distribution of both genders in the 
2010 NSQIP database. This database included additional baseline variables which were 
not available in the 2014 one: preoperative cerebrovascular accidents, chemotherapy 
within 30 days before surgery, radiation therapy in the preceding 90 days, and alcohol 
>2 drinks/day in the two weeks preceding admission. These variables were adjusted for 
in model 2. Readmission data were not available for the 2010 cohort. 
Colon cancer patients with thrombocytopenia or thrombocytosis constituted 16.16% of 
the whole colon cancer patient population, yet, they accounted for 33.95% of the deaths 
(Table IV). Mortality and composite morbidity were more prevalent in groups I and V, 
and this increased risk persisted after adjusting for confounders in models 1 and 2. 
Patients in groups I, IV, and V were also more likely to be hospitalized for at least five 
days, which also persisted after adjusting for confounders (Table IV, supplementary 
table I). This supports the above findings where platelets are an independent predictor 
of morbidity and mortality in colon cancer patients. 
Discussion 
This multicenter study is the first to establish an association between preoperative 
platelet counts and postoperative outcomes in a large cohort of patients. It provides an 
insight into platelets whose clinical role beyond hemostasis is very little appreciated.  
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Higher platelet counts have been associated with more aggressive cancers.[1, 2] This is 
potentially related to the increased inflammatory environment associated with 
malignancy which is known to induce thrombopoiesis, or the contribution of platelets to 
cancer invasiveness and thrombophilia. There is evidence that platelets also play roles 
in tissue regeneration[4, 22] and fighting infections,[3] although human studies are still 
lacking. Our findings of superior postoperative outcomes in patients with platelets in the 
low- and mid-normal ranges are consistent with the above premises. 
Anemia has been shown to predict worse postoperative outcomes in noncardiac 
surgery.[5]  Patients in categories I, IV, and V were more likely to be anemic in this 
study. Chronic inflammation often results in both anemia and thrombopoiesis, and 
anemia in turn can induce platelet production, all resulting in increased anemia 
prevalence in groups IV and V. On the other hand, cancer or therapy-induced bone 
marrow suppression or consumptive coagulopathy can induce anemia and 
thrombocytopenia, explaining the higher prevalence of anemia in group I. Nevertheless, 
adjusting for preoperative transfusions and anemia of any severity showed that platelets 
independently predicted outcomes regardless of anemia status (Table III).  
This study comprises a large number of patients from hundreds of hospitals including 
international sites, relies on a robust, prospective data collection as evidenced by strict 
quality measures and validation studies, and thoroughly adjusts for comorbidities that 
are provided in the ACS NSQIP database. Our study also bears some limitations: 1) 
Patient follow-up is until 30 days and thus, complications and death beyond that period 
are not recorded. 2) The data is deposited by NSQIP participating hospitals, and does 
not necessarily represent other non-participating facilities. 3) Around 9% of the patients 
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had their platelet counts >28 days from time of surgery and that might not represent the 
numbers shortly before operation. 4) The observational nature of the study cannot 
establish a causal relationship between platelet counts and outcomes. Importantly, 
mean platelet volume (MPV) and platelet distribution width (PDW) can provide insight 
into platelet function beyond platelet counts. Indeed, recent studies demonstrated a 
prognostic value of these parameters in different types of cancer.[32, 33, 34, 35] 
Therefore, it is imperative that future studies address the significance of platelet 
parameters besides their counts in predicting postoperative outcomes. Data on MPV 
and PDW are not available in the NSQIP database.  
 
 
 
 
 
 
 
Conclusions 
This work shows that both low and high platelet counts are independent predictors of 
increased mortality in cancer surgery. Even patients with normal platelet counts have an 
increased risk if their counts are in the upper third of the normal range. Platelet counts 
also uniformly predicted hospitalization time, 30-day readmission, and specific 
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morbidities. This is true in younger and elderly patients, both genders, and regardless of 
cancer metastasis. Importantly, these findings were validated in an independent, large, 
multicenter cohort of colon cancer patients. Future studies should investigate treating 
patients with platelet products or antiplatelet drugs as the role of platelets besides 
hemostasis is increasingly recognized. 
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Table I. Baseline variables and preoperative comorbidities in the 2014 cohort. aCardiac, 
gynecology, neurosurgery, orthopedics, otolaryngology, plastics, thoracic, urology, vascular, and 
interventional radiology. bTransfusion within 72 hours before surgery. RVU: Relative Value 
Unit; a measure implemented by the US Medicare to determine reimbursement based on case 
complexity. ASA: American Society of Anesthesiologists; classes range from I to VI. I: Healthy; 
II: mild systemic disease; III: severe systemic disease, IV: severe systemic life threatening 
disease; V: moribund and will not survive without the surgery; VI: dead. CI: Confidence 
Interval. COPD: Chronic Obstructive Pulmonary Disease. Platelet groups were compared using 
χ2 test for categorical variables and Analysis of Variance (ANOVA) for continuous variables. All 
variables showed statistical difference among groups with p<0.0001, except acute renal failure 
(p=0.19). Given the large number of patients, the differences among platelet groups were often 
statistically significant despite being small and not necessarily clinically significant. 
Baseline Variables\Platelet Count 
(x103/µL) 
(I) <150 
n=6,378 
(7.03 %) 
(II) 150-
232  
n=34,794 
(38.35 %) 
(III) 233-
316 
n=33,371 
(36.78 %) 
(IV) 317-
400 
n=11,192 
(12.33 %) 
(V) >400 
n=5,000 
(5.51 %) 
Age ≥65 years (%) 56.08 49.97 43 42.29 42.26 
Sex (female)  37.97 47.15 63.02 69.33 65.28 
Race (white)  79.84 77.75 76.87 75.04 73.68 
Surgical subspecialty 
General  58.44 53.74 57.98 61.93 64.50 
Othera 41.56 46.26 42.02 38.08 35.50 
Work RVU, mean [95% CI] 
25.09 
[24.77-
25.42] 
23.87 
[23.75-
24.00] 
23.02 
[22.90-
23.15] 
23.52 
[23.30-
23.73] 
25.35 
[25.04-
25.67] 
General anesthesia 97.04 97.24 97.35 97.59 98.66 
ASA class 
I–II  25.63 40.72 44.50 40.90 32.70 
III 63.99 53.86 50.99 53.86 59.40 
IV–V  10.16 5.22 4.32 5.03 7.80 
Infected surgical wound class  1.38 0.90 1.18 2.41 6.14 
Total operation time, mean [95% 
CI] 
194.97 
(191.55-
198.40) 
184.15 
(182.80-
185.49) 
179.51 
(178.17-
180.86) 
180.64 
(178.29-
182.99) 
193.00 
(189.25-
196.75) 
Inpatient status  79.52 73.55 70.80 74.86 86.76 
Days from admission to operation 
0 86.12 90.95 90.70 86.67 78.34 
1 3.67 2.81 2.92 3.52 6.00 
>1 10.21 6.24 6.38 9.81 15.66 
Emergency case  2.23 1.47 1.75 3.21 5.74 
Preoperative transfusionb 2.59 0.95 0.96 2.13 4.60 
Functional status 
Independent 97.12 98.08 98.11 97.73 96.46 
Partially dependent  2.10 1.33 1.34 1.72 2.82 
Dependent  0.34 0.18 0.17 0.29 0.42 
Cardiovascular variables 
Dyspnea      
None 91.28 93.43 93.24 91.74 89.84 
With moderate exertion 8.03 6.18 6.36 7.61 9.30 
At rest 0.69 0.40 0.40 0.65 0.86 
Congestive heart failure in previous 
30 days  
1.27 0.71 0.50 0.52 0.66 
Hypertension requiring medication  55.33 51.51 49.58 49.24 47.28 
Respiratory variables 
Tobacco use in past year  15.58 14.72 16.65 19.03 21..02 
History of severe COPD  6.30 5.19 5.22 6.48 6.46 
Ventilator-dependent in previous 48 
h 
0.33 0.11 0.07 0.13 0.22 
Hepatobiliary variables 
Ascites in 30 previous days  1.30 0.42 0.80 1.70 5.24 
Renal variables 
Acute renal failure 0.22 0.16 0.13 0.14 0.24 
Presently on dialysis 1.32 0.58 0.32 0.21 0.30 
Hemato-oncological variables 
Bleeding disorder 11.52 2.57 1.81 1.82 2.90 
Weight loss >10% in previous 6 
months 
5.08 3.17 3.78 6.13 12.56 
Disseminated cancer 18.89 11.73 10.76 15.12 24.22 
Other variables 
Body-mass index      
<18.5 2.82 2.12 2.39 3.37 6.30 
18.5-30 62.70 61.54 59.52 60.59 63.52 
>30 34.48 36.34 38.10 36.04 30.18 
Diabetic on oral drugs or insulin  8.45 5.62 5.38 5.92 5.88 
Open wound (with or without 
infection) 
1.24 0.78 0.84 1.19 2.26 
Steroid use for chronic condition 6.19 3.75 3.44 3.96 3.82 
Systemic sepsis in previous 48 h  2.45 1.21 1.39 2.84 8.12 
Days from platelet measurement to operation 
0-14 77.39 74.47 74.26 75.85 82.74 
15-28 14.08 16.04 16.45 15.12 11.34 
29-56 6.60 7.29 7.08 6.92 4.70 
57+ 1.93 2.20 2.22 2.11 1.22 
Preoperative lab values 
Na<136 mmol/L 10.73 7.80 9.35 14.42 22.68 
Na>145 mmol/L 2.03 1.64 1.37 1.13 0.97 
Creatinine <61.9 µmol/L 16.41 15.85 21.17 25.59 28.73 
Creatinine >132.6 µmol/L 8.77 5.21 3.84 3.84 3.88 
BUN <2.9 mmol/L 5.57 4.20 5.37 7.91 12.28 
BUN >7.1 mmol/L 25.88 21.26 16.94 15.98 14.73 
Albumin <35 g/L 24.41 13.12 13.88 23.22 43.72 
Albumin >55 g/L 0.15 0.06 0.05 0.14 0.10 
Total Bilirubin <5.1 µmol/L 5.60 6.67 10.42 15.13 18.44 
Total Bilirubin >17.1 µmol/L 17.07 9.03 6.81 7.08 8.38 
AST <10 U/L 1.09 1.18 1.36 1.91 2.70 
AST >40 U/L 20.55 9.63 8.21 9.80 13.05 
Alk Phos <30 U/L 0.47 0.39 0.49 0.31 0.33 
Alk Phos >120 U/L 19.15 10.50 11.43 16.11 26.08 
WBC <4,000 cells/µL 18.37 6.28 2.87 1.67 0.76 
WBC >10.000 cells/µL 6.77 6.90 12.68 22.42 40.25 
INR >1.2  11.51 5.93 5.37 7.36 13.34 
HCT <35% 30.97 16.45 17.95 30.69 56.58 
HCT>50% 0.74 0.92 0.47 0.34 0.32 
PTT <25 s 11.53 11.26 10.90 11.72 10.89 
PTT >35 s 14.45 8.99 8.68 11.02 16.12 
Cancer type 
Trachea, bronchus and lung  4.12 4.02 4.12 4.15 4.10 
Breast 11.30 17.50 22.63 20.03 8.46 
Prostate 6.71 10.65 6.52 3.02 1.20 
Colorectal 18.17 18.21 19.53 24.57 35.36 
Uterus 2.09 4.43 6.84 7.53 6.48 
Melanoma 0.83 0.74 0.61 0.29 0.24 
Bladder 9.11 6.84 4.67 3.76 3.24 
Other 47.66 37.61 35.07 36.64 40.92 
Table II. Mortality, morbidity, hospitalization time, and readmission rates in the 2014 
cohort. Data includes odds ratios (OR) and 95% confidence intervals (CI). OR1 and OR2 adjust 
for variables indicated in supplementary table 1.  
Outcomes\Platelet Count 
(x103/µL) 
(I) <150 
n=6,378 
(7.03 %) 
(II) 150-232  
n=34,794 
(38.35 %) 
(III) 233-
316 
n=33,371 
(36.78 %) 
(IV) 317-
400 
n=11,192 
(12.33 %) 
(V) >400 
n=5,000 
(5.51 %) 
30-day mortality 
Count (%) 183 (2.87) 410 (1.18) 344 (1.03) 175 (1.56) 148 (2.96) 
ORunadjusted 
2.84 (2.37-
3.40 
1.14 (0.99-
1.32) 
1.00 
1.53 (1.27-
1.83) 
2.93 (2.41-
3.56) 
OR1 
1.72 (1.43-
2.07) 
0.95 (0.82-
1.10) 
1.00 
1.48 (1.23-
1.78) 
2.41 (1.97-
2.94) 
OR2 
1.49 (1.23-
1.81) 
0.98 (0.84-
1.13) 
1.00 
1.29 (1.06-
1.55) 
1.78 (1.45-
2.19) 
Composite morbidity 
Count (%) 
1689 
(26.48) 
5773 
(16.59) 
5369 
(16.09) 
2518 (22.5) 
1794 
(35.88) 
ORunadjusted 
1.88 (1.76-
2.00) 
1.04 (1.00-
1.08) 
1.00 
1.51 (1.44-
1.60) 
2.92 (2.74-
3.11) 
OR1 
1.45 (1.36-
1.55) 
0.94 (0.90-
0.98) 
1.00 
1.50 (1.42-
1.59) 
2.64 (2.46-
2.82 
OR2 
1.34 (1.25-
1.43) 
0.95 (0.90-
0.99) 
1.00 
1.41 (1.33-
1.49) 
2.20 (2.05-
2.36) 
Readmission within 30 days 
Count (%) 703 (11.10) 2850 (8.28) 2617 (7.91) 1013 (9.11) 565 (11.37) 
ORunadjusted 
1.45 (1.33-
1.59) 
1.05 (0.99-
1.11) 
1.00 
1.17 (1.08-
1.26) 
1.49 (1.36-
1.64) 
OR1 
1.21 (1.11-
1.32) 
0.98 (0.93-
1.04) 
1.00 
1.15 (1.07-
1.24) 
1.36 (1.23-
1.50) 
OR2 
1.13 (1.04-
1.24) 
0.99 (0.93-
1.04) 
1.00 
1.11 (1.03-
1.20) 
1.23 (1.11-
1.36) 
Hospital stay ≥5 days 
Count (%) 
2,986 
(46.89) 
12,250 
(35.24) 
11,054 
(33.15) 
4,571 
(40.89) 
2,930 
(58.67) 
ORunadjusted 
1.78 (1.69-
1.88) 
1.10 (1.06-
1.13) 
1.00 
1.40 (1.34-
1.46) 
2.86 (2.69-
3.04) 
OR1 
1.25 (1.18-
1.34) 
0.92 (0.89-
0.96) 
1.00 
1.47 (1.40-
1.55) 
2.80 (2.61-
3.00) 
OR2 
1.14 (1.06-
1.22) 
0.94 (0.90-
0.98) 
1.00 
1.34 (1.27-
1.42) 
2.14 (1.99-
2.31) 
Specific Morbidities 
Cardiac 
Count (%) 81 (1.27) 307 (0.88) 211 (0.63) 86 (0.77) 61 (1.22) 
ORunadjusted 
2.02 (1.56-
2.62) 
1.40 (1.17-
1.67) 
1.00 
1.22 (0.95-
1.57) 
1.94 (1.46-
2.58) 
OR1 
1.29 (1.00-
1.68) 
1.17 (0.98-
1.40) 
1.00 
1.18 (0.92-
1.53) 
1.63 (1.22-
2.17) 
OR2 
1.22 (0.94-
1.59) 
1.19 (1.00-
1.42) 
1.00 
1.13 (0.88-
1.46) 
1.49 (1.12-
2.00) 
Respiratory 
Count (%) 363 (5.69) 1050 (3.02) 882 (2.64) 436 (3.90) 253 (5.06) 
ORunadjusted 
2.22 (1.96-
2.52) 
1.15 (1.05-
1.26) 
1.00 
1.49 (1.33-
1.68) 
1.96 (1.70-
2.27) 
OR1 
1.45 (1.28-
1.65) 
0.97 (0.89-
1.07) 
1.00 
1.46 (1.30-
1.65) 
1.63 (1.41-
1.89) 
OR2 
1.36 (1.19-
1.55) 
1.00 (0.91-
1.09) 
1.00 
1.34 (1.19-
1.52) 
1.37 (1.18-
1.59) 
CNS 
Count (%) 23 (0.36) 81 (0.23) 71 (0.21) 34 (0.30) 24 (0.48) 
ORunadjusted 
1.70 (1.06-
2.72) 
1.09 (0.80-
1.51) 
1.00 
1.43 (0.95-
2.15) 
2.26 (1.42-
3.60) 
OR1 
1.19 (0.74-
1.91) 
0.96 (0.69-
1.32) 
1.00 
1.39 (0.92-
2.09) 
1.95 (1.22-
3.11) 
OR2 
1.16 (0.71-
1.87) 
0.97 (0.70-
1.34) 
1.00 
1.33 (0.88-
2.01) 
1.80 (1.13-
2.88) 
Urinary 
Count (%) 283 (4.44) 963 (2.77) 799 (2.39) 355 (3.17) 162 (3.24) 
ORunadjusted 
1.89 (1.65-
2.17) 
1.16 (1.06-
1.28) 
1.00 
1.34 (1.18-
1.52) 
1.37 (1.15-
1.62) 
OR1 
1.49 (1.30-
1.72) 
1.07 (0.97-
1.18) 
1.00 
1.28 (1.13-
1.46) 
1.17 (0.99-
1.40) 
OR2 
1.41 (1.22-
1.63) 
1.08 (0.98-
1.19) 
1.00 
1.23 (1.08-
1.40) 
1.05 (0.88-
1.24) 
Wound 
Count (%) 480 (7.53) 2044 (5.87) 1931 (5.79) 837 (7.48) 549 (10.98) 
ORunadjusted 
1.33 (1.19-
1.47) 
1.02 (0.95-
1.08) 
1.00 
1.32 (1.21-
1.43) 
2.01 (1.82-
2.22) 
OR1 
1.08 (0.97-
1.20) 
0.95 (0.89-
1.01) 
1.00 
1.28 (1.17-
1.39) 
1.78 (1.61-
1.97) 
OR2 
1.04 (0.93-
1.16) 
0.96 (0.89-
1.02) 
1.00 
1.23 (1.13-
1.34) 
1.55 (1.39-
1.71) 
Sepsis 
Count (%) 322 (5.05) 1051 (3.02) 914 (2.74) 467 (4.17) 338 (6.76) 
ORunadjusted 
1.89 (1.66-
2.15) 
1.11 (1.01-
1.21) 
1.00 
1.55 (1.38-
1.73 
2.58 (2.27-
2.93) 
OR1 
1.31 (1.14-
1.50) 
0.96 (0.87-
1.05) 
1.00 
1.52 (1.35-
1.70) 
2.20 (1.92-
2.51) 
OR2 
1.21 (1.05-
1.39) 
0.98 (0.89-
1.07) 
1.00 
1.36 (1.21-
1.53) 
1.57 (1.37-
1.80) 
  
 
 
Venous Thromboembolic 
Count (%) 145 (2.27) 484 (1.39) 470 (1.41) 206 (1.84) 147 (2.94) 
ORunadjusted 
1.63 (1.35-
1.97) 
0.99 (0.87-
1.12) 
1.00 
1.31 (1.11-
1.55) 
2.12 (1.76-
2.56) 
OR1 
1.23 (1.02-
1.49) 
0.89 (0.78-
1.02) 
1.00 
1.28 (1.08-
1.51) 
1.85 (1.53-
2.23) 
OR2 
1.13 (0.93-
1.37) 
0.89 (0.78-
1.01) 
1.00 
1.20 (1.02-
1.42) 
1.56 (1.28-
1.88) 
Intra/post-operative transfusion  
Count (%) 972 (15.24) 2602 (7.48) 2493 (7.47) 
1325 
(11.84) 
1210 
(24.20) 
ORunadjusted 
2.23 (2.06-
2.41) 
1.00 (0.95-
1.06) 
1.00 
1.66 (1.55-
1.78) 
3.95 (3.66-
4.27) 
OR1 
1.74 (1.60-
1.90) 
0.92 (0.87-
0.98) 
1.00 
1.61 (1.49-
1.73) 
3.54 (3.27-
3.84) 
OR2 
1.56 (1.43-
1.70) 
0.92 (0.86-
0.97) 
1.00 
1.50 (1.39-
1.61) 
2.89 (2.66-
3.14) 
Table III. Stratified analysis by age, gender, and cancer dissemination status (2014). Data 
includes OR and 95% CI. OR1 and OR2 adjust for variables indicated in supplementary table 1.  
 
Outcomes\Platelet Count 
(x103/µL) 
(I) <150 
n=6,378 
(7.03 %) 
(II) 150-232  
n=34,794 
(38.35 %) 
(III) 233-
316 
n=33,371 
(36.78 %) 
(IV) 317-
400 
n=11,192 
(12.33 %) 
(V) >400 
n=5,000 
(5.51 %) 
30-day mortality 
Age 
<65 years (n=48,579) 
ORunadjusted 
4.77 (3.41-
6.68) 
1.34 (1.01-
1.79) 
1.00 
1.55 (1.07-
2.23) 
4.14 (2.92-
5.86) 
OR2 
1.95 (1.36-
2.79) 
1.18 (0.88-
1.58) 
1.00 
1.16 (0.79-
1.68) 
1.57 (1.09-
2.28) 
≥65 years (n=42,156) 
ORunadjusted 
1.96 (1.58-
2.44) 
0.97 (0.82-
1.15) 
1.00 
1.54 (1.25-
1.91) 
2.58 (2.03-
3.27) 
OR2 
1.23 (0.98-
1.55) 
0.93 (0.78-
1.10) 
1.00 
1.22 (0.98-
1.53) 
1.48 (1.15-
1.90) 
Sex 
Male (n=39,856) 
ORunadjusted 
2.02 (1.61-
2.54) 
0.96 (0.80-
1.16) 
1.00 
1.62 (1.25-
2.09) 
2.64 (2.00-
3.49) 
OR2 
1.42 (1.12-
1.81) 
0.99 (0.82-
1.20) 
1.00 
1.23 (0.94-
1.60) 
1.45 (1.08-
1.94) 
Female (n=50,879) 
ORunadjusted 
3.51 (2.60-
4.75) 
1.13 (0.89-
1.43) 
1.00 
1.60 (1.23-
2.09) 
3.39 (2.57-
4.46) 
OR2 
1.42 (1.03-
1.98) 
0.97 (0.76-
1.23) 
1.00 
1.19 (0.91-
1.57) 
1.60 (1.20-
2.15) 
Cancer Dissemination 
Local (n=78,954) 
ORunadjusted 
2.81 (2.21-
3.56) 
1.20 (1.00-
1.44) 
1.00 
1.38 (1.08-
1.76) 
2.45 (1.85-
3.23) 
OR2 
1.47 (1.14-
1.88) 
1.00 (0.83-
1.21) 
1.00 
1.18 (0.92-
1.51) 
1.44 (1.08-
1.92) 
Disseminated (n=11,781) 
ORunadjusted 
1.89 (1.42-
2.52) 
0.99 (0.78-
1.26) 
1.00 
1.34 (1.01-
1.78) 
1.93 (1.45-
2.57) 
OR2 
1.38 (1.01-
1.88) 
1.01 (0.78-
1.30) 
1.00 
1.21 (0.89-
1.63) 
1.54 (1.13-
2.08) 
Composite morbidity 
Age 
<65 years (n=48,579) 
ORunadjusted 
2.18 (1.98-
2.39) 
1.07 (1.01-
1.14) 
1.00 
1.52 (1.41-
1.63) 
3.22 (2.95-
3.51) 
OR2 
1.30 (1.17-
1.44) 
0.98 (0.92-
1.05) 
1.00 
1.30 (1.20-
1.41) 
1.83 (1.66-
2.02) 
≥65 years (n=42,156) 
ORunadjusted 
1.56 (1.43-
1.69) 
0.96 (0.91-
1.02) 
1.00 
1.53 (1.42-
1.65) 
2.65 (2.41-
2.92) 
OR2 
1.20 (1.09-
1.31) 
0.94 (0.88-
1.00) 
1.00 
1.27 (1.16-
1.38) 
1.58 (1.42-
1.76) 
Sex 
Male (n=39,856) 
ORunadjusted 
1.47 (1.36-
1.60) 
0.92 (0.87-
0.97) 
1.00 
1.57 (1.44-
1.71) 
2.66 (2.39-
2.96) 
OR2 
1.21 (1.11-
1.33) 
0.95 (0.89-
1.01) 
1.00 
1.31 (1.20-
1.44) 
1.76 (1.57-
1.97) 
Female (n=50,879) 
ORunadjusted 
2.16 (1.95-
2.38) 
1.04 (0.98-
1.10) 
1.00 
1.56 (1.46-
1.67) 
3.19 (2.93-
3.46) 
OR2 
1.29 (1.15-
1.44) 
0.97 (0.91-
1.03) 
1.00 
1.27 (1.18-
1.37) 
1.69 (1.54-
1.85) 
Cancer Dissemination 
Local (n=78,954) 
ORunadjusted 
1.89 (1.76-
2.03) 
1.06 (1.01-
1.11) 
1.00 
1.45 (1.37-
1.54) 
2.84 (2.64-
3.06) 
  
 
 
 
 
OR2 
1.28 (1.18-
1.38) 
0.97 (0.93-
1.02) 
1.00 
1.25 (1.17-
1.33) 
1.71 (1.57-
1.86) 
Disseminated (n=11,781) 
ORunadjusted 
1.35 (1.18-
1.55_ 
0.89 (0.81-
0.98) 
1.00 
1.48 (1.31-
1.67) 
2.10 (1.83-
2.40) 
OR2 
1.13 (0.98-
1.31) 
0.90 (0.81-
1.00) 
1.00 
1.37 (1.21-
1.56) 
1.63 (1.42-
1.89) 
1 
 
Table IV. Platelet counts predict outcomes in the year of 2010 validation dataset of colon 
cancer patients. Data includes OR and 95% CI. OR1 and OR2 adjust for variables indicated in 
supplementary table 1.  
Outcomes\Platelet Count 
(x103/µL) 
(I) <150 
n=660  
(6.56 %) 
(II) 150-232  
n=3,446 
(34.25 %) 
(III) 233-
316 
n=3,500 
(34.79 %) 
Reference 
(IV) 317-
400 
n=1,488 
(14.79 %) 
(V) >400 
n=966  
(9.60 %) 
30-day mortality 
Count (%) 35 (5.30) 71 (2.06) 46 (1.31) 27 (1.81) 39 (4.04) 
ORunadjusted 
4.20 (2.69-
6.58) 
1.58 (1.09-
2.30) 
1.00 
1.39 (0.86-
2.24) 
3.16 (2.05-
4.87) 
OR1 
2.66 (1.66-
4.25) 
1.36 (0.93-
2.00) 
1.00 
1.21 (0.74-
1.97) 
2.76 (1.76-
4.33) 
OR2 
2.51 (1.54-
4.08) 
1.43 (0.97-
2.11) 
1.00 
1.18 (0.72-
1.93) 
2.33 (1.47-
3.69) 
Composite morbidity 
Count (%) 229 (34.70) 913 (26.49) 915 (26.14) 427 (28.70) 379 (39.23) 
ORunadjusted 
1.50 (1.26-
1.79) 
1.02 (0.92-
1.13) 
1.00 
1.14 (0.99-
1.30) 
1.82 (1.57-
2.12) 
OR1 
1.29 (1.07-
1.55) 
0.96 (0.86-
1.07) 
1.00 
1.09 (0.95-
1.25) 
1.74 (1.49-
2.03) 
2 
 
 
 
 
 
OR2 
1.22 (1.01-
1.47) 
0.95 (0.85-
1.07) 
1.00 
1.08 (0.94-
1.25) 
1.67 (1.43-
1.95) 
Hospital stay ≥5 days 
Count (%) 
514  
(78.23) 
2435 
(70.74) 
2493 
(71.35) 
1125 
(75.91) 
761  
(79.11) 
ORunadjusted 
1.44 (1.18-
1.76) 
0.97 (0.88-
1.08) 
1.00 
1.27 (1.10-
1.46) 
1.52 (1.28-
1.80) 
OR1 
1.25 (1.01-
1.54) 
0.91 (0.81-
1.01) 
1.00 
1.23 (1.06-
1.42) 
1.48 (1.24-
1.76) 
OR2 
1.18 (0.96-
1.46) 
0.89 (0.80-
0.99) 
1.00 
1.20 (1.04-
1.39) 
1.39 (1.16-
1.67) 
Supplementary material for Rachidi et al.  “Preoperative platelet counts and postoperative outcomes 
in cancer surgery: a multicenter, retrospective cohort study”. 
 
 
Supplementary table I. Baseline variables adjusted for in the regression models. aOR1 2010 and 2014. bOR2 2014. cOR2 2014 stratified. 
dOR2 2010. *Variable available in 2010 dataset only. #Outcome available in 2014 dataset only. 
Baseline 
Variable\Outcome 
Variable 
Mortality Overall 
Complications 
Cardiac Resp CNS Urinary Wound Sepsis Venous Intra/postop 
transfusion 
Hospitalization 
Time 
30-day 
Readmission 
# 
Age a,b,c,d  a,b,c,d  a,b,c a,b,c a,b,c a,b,c a,b,c a,b,c a,b,c a,b,c a,b,c,d a,b,c 
Sex a,b,c,d  a,b,c,d  a,b,c a,b,c a,b,c a,b,c a,b,c a,b,c a,b,c a,b,c a,b,c,d a,b,c 
Race a,b,c,d  a,b,c,d  a,b,c a,b,c a,b,c a,b,c a,b,c a,b,c a,b,c a,b,c a,b,c,d a,b,c 
ASA class a,b,c,d  a,b,c,d  a,b,c a,b,c a,b,c a,b,c a,b,c a,b,c a,b,c a,b,c a,b,c,d a,b,c 
Inpatient status b,c,d b,c,d b,c b,c b,c b,c b,c b,c b,c b,c b,c,d b,c 
Preoperative 
transfusion 
b,c,d b,c,d b,c b,c b,c b,c b,c b,c b,c b,c b,c,d b,c 
Functional status a,b,c,d  a,b,c,d  a,b,c a,b,c a,b,c a,b,c a,b,c a,b,c a,b,c a,b,c a,b,c,d a,b,c 
History of CHF b,c,d b,c,d b,c b,c b,c b,c b,c b,c b,c b,c b,c,d b,c 
Dyspnea 
   
b,c 
        
Hypertension 
requiring 
medication 
  
b,c 
 
b,c 
       
Tobacco use in 
past year 
b,c,d b,c,d b,c b,c b,c b,c b,c b,c b,c b,c b,c,d b,c 
History of COPD b,c,d b,c,d b,c b,c b,c b,c b,c b,c b,c b,c b,c,d b,c 
Ventilator-
dependent in 
previous 48h 
   
b,c 
   
b,c 
    
Renal failure b,c,d b,c,d b,c b,c b,c b,c b,c b,c b,c b,c b,c,d b,c 
Bleeding disorder b,c,d b,c,d b,c b,c b,c b,c b,c b,c b,c b,c b,c,d b,c 
Disseminated 
cancer 
b,c,d b,c,d b,c b,c b,c b,c b,c b,c b,c b,c b,c,d b,c 
Diabetic on oral 
hypoglycemic or 
insulin 
b,c,d b,c,d b,c b,c b,c b,c b,c b,c b,c b,c b,c,d b,c 
Wound class 
      
b,c b,c 
    
Steroid use 
      
b,c b,c 
 
b,c 
  
Preoperative sepsis 
      
b,c b,c 
    
Preoperative 
hematocrit 
c c 
        
c c 
Postoperative 
diagnosis 
c c 
        
c c 
Work RVU a,b,c,d  a,b,c,d  a,b,c a,b,c a,b,c a,b,c a,b,c a,b,c a,b,c a,b,c a,b,c,d  a,b,c 
Ethanol >2 
drinks/day in 2 
weeks before 
admission* 
d d 
        
d 
 
CVA with 
neurological 
deficit* 
d d 
        
d 
 
CVA without 
neurological 
deficit* 
d d 
        
d 
 
Radiotherapy in the 
last 90 days* 
d d 
        
d 
 
Chemotherapy in 
30 days before 
surgery* 
d d 
        
d 
 
 
 
 
 
 
Table continued 
Supplementary Table II. Frequencies of missing variables in the 2014 database. 
 
Variable 
Count missing 
(% of analyzed 
patients) 
Age 0 
Sex 0 
Race 0 
Surgical subspecialty 0 
Work RVU 0 
Type of anesthesia 0 
ASA class 0 
Wound class  0 
Total operation time 0 
Inpatient/outpatient status  0 
Days from admission to operation 0 
Emergency case  0 
Preoperative transfusion 0 
Functional status 0 
Dyspnea 0 
Congestive heart failure in previous 30 days  0 
Hypertension requiring medication  0 
Tobacco use in past year  0 
History of severe COPD  0 
Ventilator-dependent in previous 48 h 0 
 Ascites in previous 30 days  0 
Acute renal failure 0 
Presently on dialysis 0 
Bleeding disorder 0 
Weight loss >10% in previous 6 months 0 
Disseminated cancer 0 
Body-mass index 0 
Diabetic on oral drugs or insulin  0 
Open wound (with or without infection) 0 
Steroid use for chronic condition 0 
Systemic sepsis in previous 48 h  0 
Days from platelet measurement to operation 0 
Serum sodium 4,429 (4.88) 
Serum creatinine 3,172 (3.50) 
BUN 7,245 (7.99) 
Albumin 28,028 (30.89) 
Total bilirubin 28,213 (31.09) 
AST 28,207 (31.09) 
Alkaline phosphatase 27,832 (30.67) 
WBC 207 (0.23) 
INR 42,754 (47.12) 
HCT 194 (0.02) 
PTT 51,838 (57.13) 
Table continued 
